Join Us in Solving Pandemic-Sized Problems

Investor Overview

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company was founded to help stop the current coronavirus pandemic (COVID-19) and prevent the next. Pardes scientists developed a novel oral antiviral treatment for COVID-19, pomotrelvir, from concept through phase 2 testing in under three years. In addition, our research efforts have generated highly potent new chemical entities with broad spectrum pan-coronavirus activity to help better prepare for future threats. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering while the company explores a range of strategic alternatives. Contact us here.

Learn More

Stock
Quote

Volume:

09/11/2023 5:04 PMEDT

Press
Releases

08/31/2023

Pardes Biosciences Announces Closing of Tender Offer

07/17/2023

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

05/05/2023

Pardes Biosciences Reports First Quarter 2023 Financial Results

04/03/2023

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19

Webcasts

Financial Information

Document Date	Description	Form	View
10/17/2022	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0000950170-22-019616.pdf 0000950170-22-019616.rtf 0000950170-22-019616.xls
11/07/2022	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0000950170-22-022610.pdf 0000950170-22-022610.rtf 0000950170-22-022610.xls
01/18/2023	Form of prospectus reflecting facts events constituting substantive change from last form	424B3	View HTML 0001193125-23-010219.pdf 0001193125-23-010219.rtf 0001193125-23-010219.xls
07/28/2023	Going private transaction by certain issuers	SC 13E3	View HTML 0001193125-23-197802.pdf 0001193125-23-197802.rtf 0001193125-23-197802.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009867.pdf 0001213900-21-009867.rtf 0001213900-21-009867.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009868.pdf 0001213900-21-009868.rtf 0001213900-21-009868.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009870.pdf 0001213900-21-009870.rtf 0001213900-21-009870.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009873.pdf 0001213900-21-009873.rtf 0001213900-21-009873.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009875.pdf 0001213900-21-009875.rtf 0001213900-21-009875.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009874.pdf 0001213900-21-009874.rtf 0001213900-21-009874.xls

Contact
IR

Send us an investor-related question using the form below.